← All Centessa Pharmaceuticals PLC filings

Centessa Pharmaceuticals PLC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
CNTA
Centessa Pharmaceuticals PLC
10-K: Centessa Pharmaceuticals Reports 2024 Financial Results, Highlights Orexin Agonist Program Progress
Centessa Pharmaceuticals' 2024 10-K filing details the company's financial status, pipeline advancements, and strategic shifts, focusing on its orexin agonist program and LockBody technology platform.
NASDAQ
CNTA
Centessa Pharmaceuticals PLC
10-K: Centessa Pharmaceuticals Reports Full Year 2023 Results, Highlights Pipeline Progress
Centessa Pharmaceuticals' 2023 annual report details financial results, pipeline advancements, and strategic shifts, including progress in hemophilia and sleep disorder programs.